Changing dynamics in the world of Plasma: is Europe ready?

Next event online

Health
starts
ends
Get in touch
Changing dynamics in the world of Plasma: is Europe ready?

About

Plasma, the liquid component of blood, contains more than 700 proteins and other substances that are vital for the functioning of the human body. It is widely used for a growing range of health treatments, particularly for rare diseases. Europe is already heavily dependent on imported plasma. COVID-19 has further exacerbated the situation, with fewer donors and rising demand for plasma transfusions from recovered COVID patients. The EU has two opportunities to rethink the approach to plasma, the pharmaceutical strategy and the revision of the Blood Products Directive.

  • Is plasma adequately addressed in plans to improve resilience of healthcare systems in Europe?
  • If we don’t want to rely on imported plasma, how do we build a more sustainable supply chain in Europe?
  • How could the Blood Products Directive incentivise more plasma donations?

Our events include photos, audio and video recording that we might use for promotional purposes. By registering, you give your permission to use your image. Should you have any questions, please contact us.

PHOTO Credit: Unsplash/Creators collective

Schedule

Schedule

Online connection of participants
Policy insight — Changing dynamics in the world of Plasma: is Europe ready? Expand Policy insight — Changing dynamics in the world of Plasma: is Europe ready?

Plasma, the liquid component of blood, contains more than 700 proteins and other substances that are vital for the functioning of the human body. It is widely used for a growing range of health treatments, particularly for rare diseases. Europe is already heavily dependent on imported plasma. COVID-19 has further exacerbated the situation, with fewer donors and rising demand for plasma transfusions from recovered COVID patients. The EU has two opportunities to rethink the approach to plasma, the pharmaceutical strategy and the revision of the Blood Products Directive.

  • Is plasma adequately addressed in plans to improve resilience of healthcare systems in Europe?
  • If we don’t want to rely on imported plasma, how do we build a more sustainable supply chain in Europe?
  • How could the Blood Products Directive incentivise more plasma donations?

speaker

Catherine Hartmann

Executive Director of the European Blood Alliance (EBA)

Martine Pergent

Chair of the International Patient Organisation for Primary Immunodeficiencies (IPOPI)

Andrzej Rys

Director for Health Systems, Medical Products and Innovation at European Commission Directorate General for Health and Food Safety

Maarten Van Baelen

Executive Director Europe at Plasma Protein Therapeutics Association (PPTA)

Moderator

Tamsin Rose

Senior Fellow for Health at Friends of Europe

End of debate
Speakers

Speakers

Martine Pergent
Martine Pergent

Chair of the International Patient Organisation for Primary Immunodeficiencies (IPOPI)

Show more information on Martine Pergent

Martine Pergent has considerable experience in Patient advocacy. As well as her position as Chair of the IPOPI, her involvement within the primary immunodeficiency disease patient community extends also to French Patient Organisation for Primary Immunodeficiency, which she co-founded in 1998. Pergent firmly believes that enabling patients to voice their experiences and needs would contribute to improving health systems, and that they should be included in the health community to the same level as healthcare professionals, decision makers and pharmaceutical companies.

Photo of Tamsin Rose
Tamsin Rose

Senior Fellow for Health at Friends of Europe

Show more information on Tamsin Rose

Tamsin Rose is Senior Fellow at Friends of Europe. Having studied international relations, she has 25 years of experience working across the European continent from Ireland to Mongolia. A natural communicator, Tamsin has been a radio reporter, worked on press for the EU Delegation in Moscow and is currently a member of the external speaker team for the European Commission Directorate General for Communication, describing how the EU works and key policies to visitor groups from around the world. Since 2002 she has specialised in public health and public participation issues, serving as Secretary General of the European Public Health Alliance (EPHA), and providing strategic advice for health groups on how to engage successfully with the EU.

Andrzej Rys
Andrzej Rys

Director for Health Systems, Medical Products and Innovation at European Commission Directorate General for Health and Food Safety

Show more information on Andrzej Rys

Andrzej Rys has held several key positions in local and national health institutions, notably serving as the Director of the Health Department of the City of Kraków, President of the Polish Public Health Foundation and Polish Deputy Minister for Health, a role which put him on the negotiation team for Poland’s accession to the EU. He later founded and led the School of Public Health and the Centre for Innovation Technology Transfer at Jagiellonian University. In 2006, Rys joined the European Commission as the Director for Public Health and Risk Assessment and was later appointed Director for Health Systems, Medical Products and Innovation at the Directorate-General for Health and Food Safety, where he works on improving EU healthcare systems for citizens.

Maarten Van Baelen
Maarten Van Baelen

Executive Director Europe at Plasma Protein Therapeutics Association (PPTA)

Show more information on Maarten Van Baelen

Maarten Van Baelen has considerable experience in the life sciences arena. In addition to advocating for access to generic, biosimilar and value-added medicines, he has represented the pharmaceutical sector’s interest in public forums, strategic policy development, and advocacy on key issues with the European Commission, National Competent Authorities, and other stakeholders. In his current position, Van Baelen is the senior point of contact for the plasma protein therapeutics industry. He is responsible for the management of health policy-related issues at the European and national levels, including programs and activities in support of PPTA’s global goals and objectives.

Partners

Partners

Insights

view all insights

Next Event

view all events
Track title

Category

00:0000:00
Stop playback
Video title

Category

Close

We use cookies to improve your online experience.
For more information, visit our privacy policy

Africa initiative logo

Stay informed

Dismiss